Evidence map›Paper›PMID 28168859›Full record

ArticleThe FEBS journal2017

Zebrafish screens for new colitis treatments - a bottom-up approach.

Jou A Lee, Stephen A Renshaw

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in The FEBS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Comparative ovarian morphophysiology ofAnimal reproduction · 2025
    Article
  3. Review
  4. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.Medical sciences (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jou A LeeThe Bateson Centre and Department of Infection, Immunity and Cardiovascular Disease, the University of Sheffield, Sheffield, UK.
Stephen A RenshawThe Bateson Centre and Department of Infection, Immunity and Cardiovascular Disease, the University of Sheffield, Sheffield, UK.
University of Sheffield · GB

Funding

Medical Research Council MR/M004864/1Wellcome Trust WT107268MA
6 · The paper itself

Abstract

Many factors interact in the development and progression of inflammatory bowel disease. This complexity demands a combination of methods to disentangle the pathology of this disease. As reported by Oehlers et al. in this issue, the zebrafish drug screen is one simple approach that could enable the elucidation of the pathways involved in IBD and ultimately the discovery of new therapeutics.

Indexed as

High-Throughput Screening AssaysAnimalsAnimals, Genetically ModifiedAnti-Inflammatory AgentsColitis, UlcerativeCrohn DiseaseDextran SulfateDisease Models, AnimalDysbiosisHumansImmunologic FactorsIntestinesNeutrophilsTrinitrobenzenesulfonic AcidZebrafishAnti-Inflammatory AgentsDextran SulfateImmunologic FactorsTrinitrobenzenesulfonic Acid

Identifiers

PMID28168859
OpenAlexW2586246378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.